Mounjaro vs Zepbound: Same Drug, Different Labels Explained
Mounjaro vs Zepbound: Same Drug, Different Labels Explained
By Dr. Onikepe Adegbola, MD PhD — Johns Hopkins-trained physician-scientist
Mounjaro and Zepbound are both tirzepatide, made by Eli Lilly. Like Ozempic/Wegovy, they're the same molecule with different FDA-approved indications. Here's what actually differs and what stays the same.
Key Takeaways
- Same drug (tirzepatide), same manufacturer (Eli Lilly), same injection device
- Mounjaro: FDA-approved for type 2 diabetes
- Zepbound: FDA-approved for weight management
- Both act on GLP-1 AND GIP receptors (dual agonist) — different from single-agonist semaglutide
- GI side effects are identical — manage with GLP-1 Digestive Enzyme Companion
Comparison
| Feature | Mounjaro | Zepbound |
|---|---|---|
| Active ingredient | Tirzepatide | Tirzepatide |
| FDA indication | Type 2 diabetes | Weight management |
| Receptors | GLP-1 + GIP (dual) | GLP-1 + GIP (dual) |
| Dose range | 2.5mg → 15mg | 2.5mg → 15mg |
| Average weight loss | ~15-22% body weight | ~15-22% body weight |
| Insurance | Better diabetes coverage | Limited weight loss coverage |
Tirzepatide vs Semaglutide
The more meaningful comparison is tirzepatide (Mounjaro/Zepbound) vs semaglutide (Ozempic/Wegovy). In the SURMOUNT-5 head-to-head trial, tirzepatide produced greater weight loss (~20% vs ~14% at 72 weeks). The dual GIP/GLP-1 mechanism may produce better metabolic outcomes but also means more complex GI effects.
Regardless of which you take, the GI management protocol is the same:
- GLP-1 Digestive Enzyme Companion with every meal
- Probiotics daily for microbiome support
- Psyllium fiber for constipation
- Low FODMAP protein to preserve muscle mass
See our detailed side-effect guides: Mounjaro nausea, Zepbound bloating, Mounjaro plateau.
This article is educational only. Medication selection requires medical evaluation.
